Late-stage clinical biopharmaceutical company Clearside Biomedical, Inc. recently announced positive preliminary results for its Phase 2 clinical trial evaluating concomitant administration of suprachoroidal Zuprata™ — Clearside’s proprietary form of triamcinolone acetonide — in combination with intravitreal aflibercept (Eylea®) for the treatment of macular edema associated with retinal vein occlusion (RVO).
According to Clearside, preliminary results from the trial — known as Tanzanite — has shown patients who received both Zuprata and Eylea (active arm) qualified for about 60 percent fewer intravitreal Eylea treatments that those patients who only received Eylea (control arm), during a three-month observation period after initial treatment. Additionally, patients who received both treatments had an average improvement of approximately 16 letters in best corrected visual acuity (BCVA) compared to 11 letters of improvement for the control group.
Click here to read the full press release.
Source: Clearside Biomedical, Inc.